Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA – Biotech Investments

 Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA 

BERKELEY, US – MAINZ, Germany – NOVEMBER 7, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA by invitation of the Rhineland-Pfalz government.

Held in Dusseldorf, Germany from 13-16 November, MEDICA draws over 4,500 exhibitors from 66 countries and more than 81,000 visitors from all over the world, making it one of the largest medical B2B trade fairs in the world. Global healthcare experts, commercial decision makers, politicians and policy makers take part in an extensive programme of first-class forums, conferences and special shows at the event.

Mr. Khairi-Taraki will be showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) throughout the event at the Rhineland-Pfalz booth which is located in Hall 3, Booth F80.

Attendees are invited to visit the booth to learn more about the critical significance of early colorectal cancer detection and to explore potential collaborations and partnership opportunities.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV 
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.

For media inquiries – press@mainzbiomed.com

In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

In the U.S.:
Josh Stanbury
+1 416 628 7441
josh@sjspr.co

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.